250 related articles for article (PubMed ID: 33425025)
1. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
[TBL] [Abstract][Full Text] [Related]
2. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
3. The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.
Wang Y; Xu J; Lan T; Zhou C; Liu P
Cancer Med; 2023 Dec; 12(24):21651-21665. PubMed ID: 37965778
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.
Francisco-Cruz A; Rocha P; Reuben A; Krishnan SN; Das P; Chen R; Quek K; Li J; Parra ER; Solis LM; Barua S; Jiang M; Lazcano R; Chow CW; Behrens C; Gumb C; Little L; Fukuoka J; Kalhor N; Weissferdt A; Kadara H; Heymach JV; Swisher S; Sepesi B; Rao A; Moran C; Zhang J; Lee JJ; Fujimoto J; Futreal PA; Wistuba II; Peterson CB; Zhang J
Mod Pathol; 2023 Jan; 36(1):100028. PubMed ID: 36788067
[TBL] [Abstract][Full Text] [Related]
5. Intratumor heterogeneity is associated with less CD8
Zhang C; Li Z; Shang X; Zhao C; Wang H
Clin Transl Oncol; 2023 Apr; 25(4):1043-1052. PubMed ID: 36422799
[TBL] [Abstract][Full Text] [Related]
6. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
[TBL] [Abstract][Full Text] [Related]
7. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
9. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY; Pan X; Hlady RA; Wagner RT; Shaikh S; Wang L; Humphreys MR; Castle EP; Stanton ML; Ho TH; Robertson KD
Clin Epigenetics; 2023 Apr; 15(1):71. PubMed ID: 37120552
[TBL] [Abstract][Full Text] [Related]
10. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
[TBL] [Abstract][Full Text] [Related]
11. Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma.
Aili A; Wen J; Xue L; Wang J
Front Oncol; 2021; 11():712765. PubMed ID: 34447697
[TBL] [Abstract][Full Text] [Related]
12. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract][Full Text] [Related]
13. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
[TBL] [Abstract][Full Text] [Related]
14. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
[TBL] [Abstract][Full Text] [Related]
16. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
17. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression.
Nguyen KB; Roerden M; Copeland CJ; Backlund CM; Klop-Packel NG; Remba T; Kim B; Singh NK; Birnbaum ME; Irvine DJ; Spranger S
Elife; 2023 Aug; 12():. PubMed ID: 37548358
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.
Tachibana H; Inakawa T; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Anticancer Res; 2022 Jun; 42(6):3151-3158. PubMed ID: 35641290
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Wang S; Chen S; Ying Y; Ma X; Shen H; Li J; Wang X; Lin Y; Liu B; Zheng X; Xie L
Front Cell Dev Biol; 2021; 9():676142. PubMed ID: 34291048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
